In Part 3 of our HER2-driven lung cancer series, Leah Phillips and thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) tackle the harder questions. They get into what resistance actually means, the difference between on-target and off-target resistance, why a cancer can sometimes transform into a different type entirely, and the emerging research and combination approaches being studied for HER2 lung cancer patients.

This is a conversation many patients will eventually need to have. The research is moving fast and there is real reason for hope.

Thanks to Boehringer Ingelheim for supporting this series. YLCI retains full editorial control.

This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

Once you know you have HER2 lung cancer, what comes next? In Part 2 of our HER2-driven lung cancer series, Leah Phillips and thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) walk through what treatment actually looks like. They cover how first-line decisions are made for early versus advanced disease, where HER2-targeted therapies fit in, how doctors tell whether a treatment is working, what brain monitoring looks like, and what a progression conversation involves.

Whether you're newly diagnosed or supporting someone through treatment, this episode will help you walk into your next oncology appointment more prepared.

Thanks to Boehringer Ingelheim for supporting this series.

YLCI retains full editorial control.

This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

In lung cancer, HER2 can mean different things.
In Part 1 of our HER2-driven lung cancer series, Leah Phillips sits down with thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) to cover the basics: what a HER2 alteration actually is, the difference between overexpression, amplification, and the exon 20 insertion mutation, why the type matters for treatment, and why next-generation sequencing at diagnosis is non-negotiable.
This is Part 1 of 3. Parts 2 and 3 cover treatment and monitoring, then resistance and emerging research.

About Dr. Kyle Concannon: Assistant Professor of Medicine-Medical Oncology at the University of Colorado and a thoracic medical oncologist at UCHealth University of Colorado Hospital. Trained as a physician-scientist at MD Anderson, his lab studies why oncogene-driven lung cancers (EGFR, HER2, ALK, ROS1) stop responding to therapy and how to overcome that resistance. He also co-hosts The @crackingcancer podcast
https://som.cuanschutz.edu/Profiles/Faculty/Profile/40545

This series is proudly sponsored by Boehringer Ingelheim.

This is educational content. Not medical advice. Always talk to your own care team about your specific situation.